Velocity Clinical Research, the leading integrated site organization for clinical trials, has launched a groundbreaking initiative: Councils to Accelerate Research Excellence (CARE Councils). The CARE Councils underpin Velocity’s dedication to supporting specialty research while providing comprehensive and strategically aligned solutions for Sponsors and CROs.
The expert-led CARE Councils bring together seasoned physicians in their areas of expertise, veteran clinicians, and operational leaders in groups designed to address specific intersections of therapeutic areas, diseases, and specialty populations. These CARE Councils meet to discuss scientific trends, review high-priority clinical trials, and refine best practices for Velocity sites worldwide.
To spearhead the launch, Velocity has announced the Diabetes and Obesity CARE Council. The urgency of enhancing research in these areas is underscored by the escalating prevalence of obesity (over 40%) and diabetes (over 11%) among U.S. adults and the respective global epidemy of these diseases with a substantial societal impact. Childhood obesity has become a particularly alarming issue — in particular, the number of children and adolescents aged 5-19 years with obesity has risen tenfold globally in the past four decades.
The Diabetes and Obesity CARE Council is led by distinguished physicians Julio Rosenstock, MD, and Juan Pablo Frías, MD. The council will leverage their vast experience in diabetes and metabolism-related research, alongside the resources of Velocity’s sites and experts that have already supported diabetes and obesity trials and offer access to millions of patient lives.
“Having dedicated my career to diabetes research, it is a privilege to lead this council to transform the way we conduct clinical research in a more efficacious fashion with participants’ safety as the top priority” said Dr. Rosenstock. “We are living incredible times in the fields of Diabetes and Obesity research, and as patients urgently need more treatment options, we need advanced approaches to clinical research.”
Dr. Frías said he looks forward to bringing together leaders across disciplines. “I’m confident in our ability to innovate. We can improve clinical trial performance by addressing the unique challenges these therapeutic areas present, while also improving the way we engage our communities to find and retain the right patients.”
Dr. Rosenstock and Dr. Frias were recently featured prominently throughout the American Diabetes Association (ADA) 83rd Scientific Sessions, and had trial results simultaneously published in the New England Journal of Medicine and The Lancet.
Having enrolled more than 13,500 participants with diabetes and/or obesity in over 1,350 endocrinology and metabolism trials, Velocity’s Principal Investigators and operational experts are already engaging with Sponsors and CROs to help review protocols, contribute to study design, and support diverse enrollment targets. The company also recently announced a partnership with Privia Health, which further expands Velocity’s reach and therapeutic breadth.
